In NSCLC, one of the most important therapeutic breakthroughs has been the development of tyrosine kinase inhibitors (TKIs) directed against activating mutations in the epidermal growth factor receptor (EGFR) gene [82]. Here, EGFR is linked to non-small cell lung carcinoma.